Dr. Matthew Alan Cunningham-Hill, MD

Dr. Cunningham-Hill practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Cunningham-Hill's NPI, 1275997348, was assigned on April 5, 2016. Dr. Cunningham-Hill holds West Virginia license 30387.

Dr. Cunningham-Hill's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Cunningham-Hill's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Cunningham-Hill is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Cunningham-Hill to 5 more hospitals, 6 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cunningham-Hill practices, 9 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Cunningham-Hill's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dmand AI has Dr. Cunningham-Hill's licenses on file in 2 states: West Virginia and Pennsylvania.

CMS data shows 1,208 Medicare services from Dr. Cunningham-Hill across 23 procedure codes in 2024, for 858 Medicare patients. Medicare paid $44,833 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 858 Medicare patients who saw Dr. Cunningham-Hill in 2024. The largest group is 65 to 74, with 371 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cunningham-Hill's median patient age at 68, with 47% women.

In 2024, Dr. Cunningham-Hill wrote 69 Medicare Part D claims for 37 patients. 91% of them were for generic drugs. CMS names the drug for 37 of them, across 1 drug with 11 or more claims each, at $235 in total drug cost. In 2023, CMS named 47 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Cunningham-Hill for performance year 2024, reported through an alternative payment model (APM). Dr. Cunningham-Hill accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 12 procedures of leg revascularization (restoring blood flow) by Dr. Cunningham-Hill, more than 66% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Varicose vein removal: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Cunningham-Hill, published from 2021 to 2023. Dr. Cunningham-Hill's most frequent co-authors are Lawrence Bamidele Oresanya, MD, Lakshmikumar Pillai, MD and Robert M. Weiss.

CMS Open Payments shows 98 general payments to Dr. Cunningham-Hill from 16 drug and device companies from 2018 to 2025. Grants make up the largest share, 48% of the total. Medtronic, Inc. paid the most, $10,580.